Fast Locator 2012-2013 Index - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Fast Locator 2012-2013 Index
View companies' outsourcing profiles from PharmTech's 2012 Outsourcing Resources Fast Locator Index in the following categories.


Pharmaceutical Technology Fast Locator – Outsourcing Resources

Analytical Services
View company profiles

Biomanufacturing
View company profiles

Commercial Manufacturing
View company profiles

Consulting
View company profiles

Development and Phase I/II/CTM
View company profiles

Packaging and Logistics
View company profiles

API Production Technologies
View company profiles

 

View the full Fast Locator Index that appeared in Pharmaceutical Technology's Outsourcing Resources 2012 guide:

Capabilities in North America [Download PDF]

Capabilities in Europe and Asia [Download PDF]

API Production Technologies [Download PDF]

 

Visit the PharmTech Outsourcing webpage.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here